Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Expenses: 2019-2025

Historic Operating Expenses for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $9.2 million.

  • Eton Pharmaceuticals' Operating Expenses rose 59.12% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year increase of 50.46%. This contributed to the annual value of $26.0 million for FY2024, which is 16.87% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Operating Expenses stood at $9.2 million, which was down 31.20% from $13.4 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Operating Expenses high stood at $13.4 million for Q2 2025, and its period low was $4.4 million during Q4 2021.
  • In the last 3 years, Eton Pharmaceuticals' Operating Expenses had a median value of $5.8 million in 2024 and averaged $7.4 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 44.31% in 2021, then spiked by 77.91% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Operating Expenses (Quarterly) stood at $4.4 million in 2021, then increased by 20.22% to $5.3 million in 2022, then climbed by 6.13% to $5.6 million in 2023, then rose by 3.98% to $5.8 million in 2024, then soared by 59.12% to $9.2 million in 2025.
  • Its Operating Expenses stands at $9.2 million for Q3 2025, versus $13.4 million for Q2 2025 and $10.3 million for Q1 2025.